Paroxysmal atrial fibrillation and hemochromatosis: a narrative review.
| Autor: | Ahmed G; Dow Medical College., Rathi S; Dow University of Health Sciences., Sidhu HK; Dayanand Medical College and Hospital, Ludhiana, India., Muzaffar M; CMH Lahore Medical College, Lahore, Pakistan., Wajid MH; King Edward Medical University., Kumari K; Ziauddin Medical University, Karachi., Fakhor H; Asselin Hedelin Hospital, Yvetot, France., Attia NM; Zagazig University, Zagazig, Egypt., Majumder K; Chittagong Medical College, Chittagong, Bangladesh., Kumar V; The Brooklyn Hospital Center, New York., Tejwaney U; Valley Health System, New Jersey, USA., Ram N; Aga Khan University Hospital. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2023 Dec 04; Vol. 86 (2), pp. 909-919. Date of Electronic Publication: 2023 Dec 04 (Print Publication: 2024). |
| DOI: | 10.1097/MS9.0000000000001605 |
| Abstrakt: | Paroxysmal atrial fibrillation (PAF) and hemochromatosis have a complex relationship. This review explores its mechanisms, prevalence, correlations, and clinical manifestations. Hereditary hemochromatosis (HH) involves iron overload due to HFE protein mutations, while atrial fibrillation (AF) is characterized by irregular heart rhythms. Iron overload in hemochromatosis can promote cardiac arrhythmias. AF is prevalent in developed countries and may be linked to cryptogenic strokes. Genetic variations and demographic factors influence the occurrence of both conditions. HH affects multiple organ systems, including the heart, while AF causes palpitations and reduced exercise tolerance. Diagnosis involves iron markers, genotypic testing, and electrocardiogram (ECG) findings. Treatment strategies focus on reducing iron levels in hemochromatosis and managing AF through antithrombotic therapy and rhythm control. Untreated hemochromatosis carries a higher risk of complications, and PAF is associated with increased cardiovascular-related mortality. For better understanding of the mechanisms and to improve management, additional studies are required. Tailored approaches and combined treatments may enhance patient outcomes. Competing Interests: No conflicts of interest were declared.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|